So they have increased their TLT to 9,192 tests the USA accounts...

So they have increased their TLT to 9,192 tests

the USA accounts for 81% of commercial tests - let’s call it 7500 tests in the USA.

Sales team is about 28 - Let’s call it an average of 20 across the last 6 month.

In the last 6month assuming 20 working days per month, each member of the sales team have sold 3 test per day each! 3 tests - really? WTF.

KP see 2% of urology patients of which there are 800,000 in the USA ( 16,000 patients)

At an average of 65 tests per day in the USA after getting KP on board is a Atrocious!

Now I know the sales team are not out selling directly, but I would say they are having very little impact. Do medical professionals have time devote to this given covid running rampant - is it wise to be expanding a sales force in a disruptive technology in the middle of a global pandemic?

I fully believe in the product and the market has huge potential - but our lab is operating at 2.8% capacity and market penetration is woefull. Having a great product is brilliant, getting the product validated and approved is another, but you have to sell it.

I still question if a medical CEO is the right for this phase of the business development.

still no update on the $20m worth of tests that were invoiced.

What does actual market penetration look like?

At the very least this 16,000 KP patients - if 50% are being monitored that’s 32,000 tests per year (750 per test is $24M - that will be profit making alone). Where is the issue?